Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated wi...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Seung Yeon Oh (15051017) (author)
مؤلفون آخرون: You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
منشور في: 2025
الموضوعات:
Cancer
Therapeutic Research and Development
Drug Resistance
Clinical drug resistance
Lung Cancer
Translational Research
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة